Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myelomonocytic, Acute 1Leukemia, Myeloid, Acute 1Leukemia, Monocytic, Acute 1Leukemia, Megakaryoblastic, Acute 1Leukemia, Erythroblastic, Acute 1Leukemia, Eosinophilic, Acute 1Leukemia, Basophilic, Acute 1Leukemia 1Congenital Abnormalities 1

Interventions

Cytarabine 6Daunorubicin 5Etoposide 3Observation 2Gemtuzumab 2Asparaginase 2valspodar 1palmitoyl-L-asparaginase 1midostaurin 1laromustine 1etoposide phosphate 1dexamethasone acetate 1aldesleukin 1Watchful Waiting 1Thioguanine 1Peripheral Blood Stem Cell Transplantation 1Mitoxantrone 1Interleukin-2 1Granulocyte Colony-Stimulating Factor 1Filgrastim 1Busulfan 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Leukemia, Eosinophilic, Acute × laromustine × Clear all
NCT00112554 2013-11-06

Cytarabine With or Without VNP40101M in Treating Patients With Relapsed Acute Myeloid Leukemia

National Cancer Institute (NCI)

Phase 3 Completed
420 enrolled
Other hematologic neoplasm

Congenital Abnormalities, Leukemia, Erythroblastic, Acute, Leukemia, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡